POZEN Inc.  

(Public, NASDAQ:POZN)   Watch this stock  
Find more results for POZN
7.90
-0.20 (-2.47%)
Dec 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.82 - 8.15
52 week 5.96 - 9.90
Open 8.15
Vol / Avg. 466,497.00/466,671.00
Mkt cap 261.48M
P/E 25.17
Div/yield 1.75
EPS 0.31
Shares 32.08M
Beta 2.01
Inst. own 57%
Dec 17, 2014
POZEN Inc. Update on 2nd CRL from the FDA for YOSPRALA Conference Call - Webcast
Nov 6, 2014
Q3 2014 POZEN Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 89.55% -161.87%
Operating margin 51.88% -162.60%
EBITD margin - -162.32%
Return on average assets 65.38% -26.75%
Return on average equity 81.48% -32.80%
Employees 16 -
CDP Score - -

Address

SUITE 400, 1414 RALEIGH ROAD
CHAPEL HILL, NC 27517
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

POZEN Inc. (POZEN), is a pharmaceutical company focused on transforming medicine. The Company had developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet is the brand name for the product combining sumatriptan 85 milligram, formulated with RT Technology and naproxen sodium 500 milligram in a single tablet designed for the acute treatment of migraine. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. On November 23, 2011, the Company entered into a Purchase and Sale Agreement with CPPIB Credit Investments Inc (CII,), pursuant to which it sold, and CII purchased, its right to receive future royalty payments arising from United States sales of MT 400, including Treximet.

Officers and directors

John R. Plachetka Pharm.D. Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
William L. Hodges CPA Chief Financial Officer, Senior Vice President - Finance and Administration
Age: 59
Bio & Compensation  - Reuters
Gilda M. Thomas J.D. Senior Vice President, General Counsel
Age: 59
Bio & Compensation  - Reuters
Dennis L. McNamara Senior Vice President, Chief Business Officer
Age: 48
Bio & Compensation  - Reuters
John E. Barnhardt CPA Vice President - Finance and Administration
Age: 64
Bio & Compensation  - Reuters
John G. Fort M.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Kenneth B Lee JR Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Neal F. Fowler Independent Director
Age: 52
Bio & Compensation  - Reuters
Arthur S. Kirsch Independent Director
Age: 62
Bio & Compensation  - Reuters
Seth A. Rudnick M.D. Independent Director
Bio & Compensation  - Reuters